- Home
- STRW vs KZIA Comparison
STRW vs KZIA Comparison
Compare STRW & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STRW | KZIA |
|---|---|---|
| Founded | 2015 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 177.4M | 154.9M |
| IPO Year | 2019 | 2002 |
Fundamental Metrics
Financial Performance| Metric | STRW | KZIA |
|---|---|---|
| Price | $14.02 | $14.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $13.88 | ★ $19.50 |
| AVG Volume (30 Days) | 34.5K | ★ 163.5K |
| Earning Date | 05-08-2026 | 06-04-2026 |
| Dividend Yield | ★ 5.17% | N/A |
| EPS Growth | ★ 5.26 | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $154,999,000.00 | N/A |
| Revenue This Year | $8.52 | N/A |
| Revenue Next Year | $3.95 | N/A |
| P/E Ratio | $81.47 | ★ N/A |
| Revenue Growth | ★ 32.41 | N/A |
| 52 Week Low | $10.00 | $4.86 |
| 52 Week High | $14.27 | $17.40 |
Technical Indicators
Market Signals| Indicator | STRW | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 59.93 | 57.85 |
| Support Level | $12.59 | $11.90 |
| Resistance Level | N/A | $14.25 |
| Average True Range (ATR) | 0.26 | 0.96 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 73.97 | 74.57 |
Price Performance
Historical ComparisonAbout STRW Strawberry Fields REIT Inc.
Strawberry Fields REIT Inc is a self-managed and self-administered company that specializes in the acquisition, ownership and triple-net leasing of skilled nursing facilities and other post-acute healthcare properties.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.